cant reduction in the

risk of DVT (0.22 vs 4.15%: RR, 0.05; 95% CI, 0.02-0.13,
P < .00,001). Among the two studies reporting
bleeding risk, there was no difference among those
receiving or not receiving prophylaxis. Although a few
included studies evaluated the efï¬cacy of fondaparinux